Actinium Pharmaceuticals has patented a method for treating cancer by administering a BCL-2 inhibitor with an alpha-emitting isotope-labeled agent. The patent specifically covers treating acute myeloid leukemia with venetoclax and 225Ac-labeled HuM195. GlobalData’s report on Actinium Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Actinium Pharmaceuticals, Antibody drug conjugates(ADC) cancer therapy was a key innovation area identified from patents. Actinium Pharmaceuticals's grant share as of January 2024 was 28%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of acute myeloid leukemia using combination pharmaceutical therapy
A recently granted patent (Publication Number: US11844799B2) discloses a method for treating acute myeloid leukemia in human subjects through a combination pharmaceutical therapy. The method involves administering venetoclax in conjunction with administering 225Ac-labeled HuM195 to the subject. This combination therapy aims to effectively target and treat acute myeloid leukemia in afflicted individuals.
Furthermore, the patent claims specify that the method is particularly beneficial for treating relapsed and/or refractory cases of acute myeloid leukemia. By combining the administration of venetoclax and 225Ac-labeled HuM195, the method offers a promising approach to address the challenges posed by relapsed and refractory forms of the disease. This innovative treatment strategy holds potential for improving outcomes and providing new therapeutic options for individuals battling acute myeloid leukemia.
To know more about GlobalData’s detailed insights on Actinium Pharmaceuticals, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
